


Metabolic monitoring for patients receiving atypical antipsychotics

Tool intended for use in monitoring and management of antipsychotics after appropriate patient assessment (e.g., indication, comorbid conditions, family history, etc.)



Legend

BMI	Body Mass Index
BG	Blood Glucose
SGA	Second Generation Antipsychotic

References:

American Diabetes Association. (2004). Consensus development conference on antipsychotic drugs and obesity and diabetes. *Diabetes care*, 27(2), 596-601.

Healthcare Effectiveness Data and Information Set (HEDIS). (2020). Metabolic Monitoring for Children and Adolescents on Antipsychotics. National Committee for Quality Assurance.

Zhang, Y., et al. (2017). The metabolic side effects of 12 antipsychotic drugs used for the treatment of schizophrenia on glucose: a network meta-analysis. *BMC psychiatry*, 17(1), 373.

Walkup, J. (2009). Practice parameter on the use of psychotropic medication in children and adolescents. *Journal of the American Academy of Child & Adolescent Psychiatry*, 48(9), 961-973.

SGA Risk of Metabolic Disturbances

Greatest

Olanzapine
 Clozapine
 Asenapine
 Quetiapine
 Paliperidone
 Risperidone
 Aripiprazole
 Ziprasidone

Least